Advertisement

Biotech ImmunoGen Inc. has earned a $2 million milestone payment from Bayer HealthCare Pharmaceuticals in the wake of Bayer submitting an Investigational New Drug application based on ImmunoGen’s Targeted Antibody Payload (TAP) technology.

The IND submission is for Bayer’s BAY 94-9343, which is under development under an agreement with ImmunoGen that grants Bayer exclusive rights to use the Waltham company’s maytansinoid TAP technology to develop anticancer therapeutics that target mesothelin.

SOURCE

Advertisement
Advertisement